← Comparing 1 hypotheses side-by-side
Add hypothesis:
— Select a hypothesis to add —
eIF2α Phosphorylation Imbalance Disrupts Mitochondrial Prote (EIF2S1,eIF2α,PERK,GCN2,ATF4,TOMM20,TIMM23,NDUFS1,NDUFS3,COX4I1,COX5A,mitochondrial protein import) — 0.00 Closed-loop transcranial focused ultrasound to restore hippo (SST) — 0.00 LDLR-Primed LRP1 Transcytosis with pH-Responsive Escape Stra (LDLR) — 0.00 GLUT1-Mediated Carrier-Conjugate Delivery Strategy (LDLR) — 0.00 TBK1 Loss Triggers Astrocyte-to-Neuron Senescence Propagatio (TBK1 → NF-κB / IRF3 / p62-autophagy / SASP effectors) — 0.00 LDLR-Mediated Neurosteroid Precursor Delivery Strategy (LDLR) — 0.00 Alpha-theta entrainment therapy to enhance default mode netw (SST) — 0.00 LAMP2A Upregulation to Enhance Chaperone-Mediated Autophagy (LAMP2A) — 0.00 TBK1 Loss Triggers eIF2α-Mediated Translational Repression T (TBK1, EIF2S1) — 0.00 LAMP1 Overexpression to Enhance Lysosomal Capacity Independe (LAMP1) — 0.00 Cell-Type-Specific TFEB Modulation Combined with Trehalose f (TFEB) — 0.00 Closed-loop transcranial focused ultrasound with gamma entra (PVALB) — 0.00 Closed-loop transcranial focused ultrasound targeting EC-II (SST) — 0.97 GluN2B-Mediated Thalamocortical Control of Glymphatic Tau Cl (GRIN2B) — 0.96 Closed-loop optogenetic targeting PV interneurons to restore (PVALB) — 0.96 Closed-loop transcranial focused ultrasound targeting EC-II (SST) — 0.96 Cortico-Striatal Synchrony Restoration via NMDA Modulation (GRIN2B) — 0.95 Gamma entrainment therapy to restore hippocampal-cortical sy (SST) — 0.95 Plasma NfL Elevation Secondary to BBB-Associated Transport D (NEFL) — 0.94 Microglial-Mediated Tau Clearance Dysfunction via TREM2 Rece (MAPT) — 0.94 Gut Microbiome Remodeling to Prevent Systemic NLRP3 Priming (NLRP3, CASP1, IL1B, PYCARD) — 0.92 Closed-loop transcranial focused ultrasound to restore hippo (CCK) — 0.91 eIF2α Phosphorylation Imbalance Creates Integrated Stress Re (EIF2S1,eIF2α,PERK,GCN2,ATF4,ATF5,CHOP,DDIT3,integrated stress response,protein synthesis) — 0.90 APOE-Dependent Autophagy Restoration (MTOR) — 0.89 Hypothesis 4: Metabolic Coupling via Lactate-Shuttling Colla (SLC16A1, SLC16A7, LDHA, PDHA1) — 0.89 p38α Inhibitor and PRMT1 Activator Combination to Restore Ph (MAPK14/PRMT1) — 0.89 SIRT1-Mediated Reversal of TREM2-Dependent Microglial Senesc (SIRT1) — 0.89 TREM2-Mediated Astrocyte-Microglia Crosstalk in Neurodegener (TREM2) — 0.89 ACSL4-Driven Ferroptotic Priming in Disease-Associated Micro (ACSL4) — 0.89 Multi-Target Hypothesis: Aβ-Induced Cholinergic Damage is Pa (APP/PSEN1 (Aβ production), CHAT (cholinergic synthesis)) — 0.89
Add
|
× NRF2-Mediated Proteostati
NFE2L2,KEAP1,HMOX1,SQSTM1,PSMB5 · neurodegeneration · comparative
Composite 0.700
Price $0.54
Evidence For 0
Evidence Against 0
Convergence hypothesis: NRF2 (NFE2L2) is the central transcriptional regulator whose failure explains parallel proteostatic collapse in both PD and AD, making it a high-priority cross-disease target.
PD-specific mechanism: NRF2 regulates ARE-containing genes (HMOX1, NQO1, GCLC, GSTM1) that detoxify reactive oxygen species generated by mitochondrial dysfunction and neuromelanin iron accumulation. In PD, KEAP1 releases NRF2 in early disease to compensate, but chronic oxidative stress (elevated 4-
Radar Chart — 10 Dimensions
Score Breakdown
Dimension NRF2-Mediated Proteostatic Con Mechanistic 0.750 Evidence 0.750 Novelty 0.650 Feasibility 0.800 Impact 0.800 Druggability 0.000 Safety 0.000 Competition 0.000 Data 0.000 Reproducible 0.500 KG Connect 0.500
Evidence NRF2-Mediated Proteostatic Convergence: Shared Oxidative Str No evidence citations yet
Price History Overlay